Transcriptome-based stemness indices analysis reveals platinum-based chemo-theraputic response indicators in advanced-stage serous ovarian cancer

References

• Amante S, Santos F, Cunha TM. Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists. Insights Imaging. 2021;12:60.
   PubMed Web of Science ®Google Scholar
• Sommerkamp P, Cabezas-Wallscheid N, Trumpp A. Alternative polyadenylation in stem cell self-renewal and differentiation. Trends Mol Med. 2021. DOI:10.1016/j.molmed.2021.04.006
   PubMed Web of Science ®Google Scholar
• Saygin C, Matei D, Majeti R, et al. Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell. 2019;24:25–40.
   PubMed Web of Science ®Google Scholar
• Tyagi K, Mandal S, Roy A. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: a promise towards disease remission. Biochim Biophys Acta Rev Cancer. 2021;1876:188563.
   PubMed Web of Science ®Google Scholar
• Roy L, Cowden Dahl KD. Can stemness and chemoresistance be therapeutically targeted via signaling pathways in ovarian cancer? Cancers (Basel). 2018;10:241.
   Web of Science ®Google Scholar
• Hajjo R, Sabbah DA, Bardaweel SK, et al. Identification of tumor-specific MRI biomarkers using machine learning (ML). Diagnostics (Basel). 2021;11. DOI:10.3390/diagnostics11050742
   PubMedGoogle Scholar
• Malta TM, Sokolov A, Gentles AJ, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173: 338–354
   PubMed Web of Science ®Google Scholar
• Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
   PubMed Web of Science ®Google Scholar
• Bai KH, He SY, Shu LL, et al. Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index. Cancer Med. 2020;9:4290–4298.
   PubMed Web of Science ®Google Scholar
• Pei J, Wang Y, Li Y. Identification of key genes controlling breast cancer stem cell characteristics via stemness indices analysis. J Transl Med. 2020;18:74.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu X, Chen C, et al. A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer. Transl Oncol. 2021;14:100901.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–D13.
   PubMed Web of Science ®Google Scholar
• Mok SC, Bonome T, Vathipadiekal V, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009;16:521–532.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Ning G, Howitt BE, et al. In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells. J Pathol. 2016;238:519–530.
   PubMed Web of Science ®Google Scholar
• Tassi RA, Gambino A, Ardighieri L, et al. FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. Br J Cancer. 2019;121:584–592.
   PubMed Web of Science ®Google Scholar
• Koti M, Gooding RJ, Nuin P, et al. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 2013;13:549.
   PubMed Web of Science ®Google Scholar
• Papadaki MA, Stoupis G, Theodoropoulos PA, et al. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol Cancer Ther. 2019;18:437–447.
   PubMed Web of Science ®Google Scholar
• Hao X, Zhao B, Zhou W, et al. Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. iScience. 2021;24:102016.
   PubMed Web of Science ®Google Scholar
• Nacarelli T, Fukumoto T, Zundell JA, et al. NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer. Cancer Res. 2020;80:890–900.
   PubMed Web of Science ®Google Scholar
• Lin S, Li X, Lin M, et al. Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer. Medicine (Baltimore). 2021;100:e24194.
   PubMed Web of Science ®Google Scholar
• Pérez-Fidalgo JA, Gambardella V, Pineda B, et al. Aurora kinases in ovarian cancer. ESMO Open. 2020;5:e000718.
   PubMed Web of Science ®Google Scholar
• Ramarao-Milne P, Kondrashova O, Barry S, et al. Histone modifying enzymes in gynaecological cancers. Cancers (Basel). 2021;13:816.
   PubMed Web of Science ®Google Scholar
• Reyes-González JM, Vivas-Mejía PE. c-MYC and epithelial ovarian cancer. Front Oncol. 2021;11:601512.
   PubMedGoogle Scholar
• Weberpals JI, Pugh TJ, Marco-Casanova P, et al. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. Cancer Med. 2021;10:3045–3058.
   PubMed Web of Science ®Google Scholar
• Lorusso D, González-Martín A, Ray-Coquard I. Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin. Future Oncol. 2021;17:9–19.
   PubMed Web of Science ®Google Scholar
• Alblihy A, Alabdullah ML, Ali R, et al. Clinicopathological and functional evaluation reveal NBS1 as a predictor of platinum resistance in epithelial ovarian cancers. Biomedicines. 2021;9:56.
   PubMed Web of Science ®Google Scholar
• Muinao T, Deka Boruah HP, Pal M. Diagnostic and prognostic biomarkers in ovarian cancer and the potential roles of cancer stem cells - an updated review. Exp Cell Res. 2018;362:1–10.
   PubMed Web of Science ®Google Scholar
• Keyvani V, Farshchian M, Esmaeili S-A, et al. Ovarian cancer stem cells and targeted therapy. J Ovarian Res. 2019;12:120.
   PubMed Web of Science ®Google Scholar
• Steinbichler TB, Dudás J, Skvortsov S, et al. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018;53:156–167.
   PubMed Web of Science ®Google Scholar
• Prasad S, Ramachandran S, Gupta N, et al. Cancer cells stemness: a doorstep to targeted therapy. Biochimica Et Biophysica Acta Mol Basis Dis. 2020;1866:165424.
   PubMed Web of Science ®Google Scholar
• Davidson B. Biomarkers of drug resistance in ovarian cancer - an update. Expert Rev Mol Diagn. 2019;19:469–476.
   PubMed Web of Science ®Google Scholar
• Gov E. Co-expressed functional module-related genes in ovarian cancer stem cells represent novel prognostic biomarkers in ovarian cancer. Syst Biol Reprod Med. 2020;66:255–266.
   PubMed Web of Science ®Google Scholar
• Wang J-H, Huang S-T, Zhang L, et al. Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma. Cancer Med. 2019;8:1315–1325.
   PubMed Web of Science ®Google Scholar
• Wesley T, Berzins S, Kannourakis G, et al. The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence. Cell Commun Signal. 2021;19:55.
   PubMed Web of Science ®Google Scholar
• Murray D, Mirzayans R. Cellular responses to platinum-based anticancer drugs and UVC: role of p53 and IMPLICATIONS FOR CANCER THERAPy. Int J Mol Sci. 2020;21:5766.
   Web of Science ®Google Scholar
• Jalalirad M, Haddad TC, Salisbury JL, et al. Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance. Oncogene. 2021;40:2509–2523.
   PubMed Web of Science ®Google Scholar
• Cai XP, Chen LD, Song HB, et al. PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells. Am J Transl Res. 2016;8:4172–4183.
   PubMed Web of Science ®Google Scholar
• Mignogna C, Staropoli N, Botta C, et al. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. J Ovarian Res. 2016;9:31.
   PubMed Web of Science ®Google Scholar
• Bansal N, Marchion DC, Bicaku E, et al. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol. 2012;23:35–42.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang X, Li X, et al. Connection between CDC20 expression and hepatocellular carcinoma prognosis. Med Sci Monit. 2021;27:e926760.
   PubMed Web of Science ®Google Scholar
• Luo M, Zeng H, Ma XY, et al. [Identification of hub genes for ovarian cancer stem cell properties with weighted gene co-expression network analysis]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2021;52:248–258.
   PubMedGoogle Scholar
• Simonetti G, Boga C, Durante J, et al. Synthesis of novel tryptamine derivatives and their biological activity as antitumor agents. Molecules. 2021;26:683.
   Web of Science ®Google Scholar
• Mao DD, Gujar AD, Mahlokozera T, et al. A CDC20-APC/SOX2 signaling axis regulates human glioblastoma stem-like cells. Cell Rep. 2015;11:1809–1821.
   PubMed Web of Science ®Google Scholar
• Liu Y, Duan C, Zhang C. E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: recent Advances and Future Potential. Front Pharmacol. 2021;12:645864.
   PubMed Web of Science ®Google Scholar
• Wu F, Lin Y, Cui P, et al. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner. Cancer Chemother Pharmacol. 2018;81:999–1006.
   PubMed Web of Science ®Google Scholar
• Chi JJ, Li H, Zhou Z, et al. A novel strategy to block mitotic progression for targeted therapy. EBioMedicine. 2019;49:40–54.
   PubMed Web of Science ®Google Scholar
• Chong T, Sarac A, Yao CQ, et al. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer. J Ovarian Res. 2018;11:27.
   PubMed Web of Science ®Google Scholar
• Zhu LJ, Pan Y, Chen XY, et al. BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation. Oncol Lett. 2020;19:3506–3512.
   PubMed Web of Science ®Google Scholar
• Xu H, Zou R, Li F, et al. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer. Cancer Med. 2021. DOI:10.1002/cam4.3907.
   Web of Science ®Google Scholar
• Liu J, Tan Z, He J, et al. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value. Biosci Rep. 2020;40. DOI:10.1042/BSR20201431.
   Web of Science ®Google Scholar
• Hu Y, Zheng M, Wang S, et al. Identification of a five-gene signature of the RGS gene family with prognostic value in ovarian cancer. Genomics. 2021;113(4):2134–2144.
   Web of Science ®Google Scholar